PEER REVIEWED, EVIDENCE-BASED INFORMATION FOR CLINICIANS AND RESEARCHERS IN NEUROSCIENCE

Category: Drug Development

Current Issue

Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review

by Waguih William IsHak, MD; Ashley Meyer, BS; Luiza Freire,

September 1, 2024 No Comments

Drug Development

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group

by Gahan J. Pandina, PhD; Joan Busner, PhD; Lucas Kempf,

March 1, 2024 No Comments

Drug Development

Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development

by Philip D. Harvey, PhD; Joan Busner, PhD; Gahan Pandina,

March 1, 2023 No Comments

Drug Development

Implications of Pediatric Initiatives on CNS Drug Development for All Ages—2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development

by Gahan Pandina, PhD; Joan Busner, PhD; Joseph P. Horrigan,

March 1, 2023 No Comments

Drug Development

Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development

by Joan Busner, PhD; Gahan Pandina, PhD; Simon Day, PhD; Atul

March 1, 2023 No Comments

Current Issue

Xanomeline and Trospium: A Potential Fixed Drug Combination (FDC) for Schizophrenia—A Brief Review of Current Data

by Alok Singh, MD Dr. Singh is with All India

December 1, 2022 No Comments

Drug Development

Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials

by Erica A. Smith, PhD; William P. Horan, PhD; Dominique

January 1, 2022 No Comments

Drug Development

Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization

by Joan Busner, PhD; Gahan Pandina, PhD; Silvia Zaragoza domingo

October 1, 2021 No Comments

Depression

The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice

by David G. Daniel, MD; Noah G. Daniel; Donald T.

September 1, 2019 No Comments

Drug Development

Correlation Between the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale and Nonmotor Scales in Patients with Parkinson’s Disease

by Erika D. Driver-Dunckley, MD; Nan Zhang, MS; Holly A.

September 1, 2019 No Comments

LATEST DIGITAL EDITION

ARCHIVES

Innovations in Clinical Neuroscience is a subsidiary of Matrix Medical Communications

contact

Links

About

Topics

©2024 Matrix Medical Communications copyright all right reserved.